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In higher vertebrates, mucosal sites at the border between the internal and external
environments, directly interact with bacteria, viruses, and fungi. Through co-evolution,
hosts developed mechanisms of tolerance or ignorance toward some infectious agents,
because hosts established “gain of function” interactions with symbiotic bacteria.
Indeed, some bacteria assist hosts in different functions, among which are digestion
of complex carbohydrates, and absorption and supply of vitamins. There is no
doubt that microbiota modulate innate and acquired immune responses starting at
birth. However, variations in quality and quantity of bacterial species interfere with
the equilibrium between inflammation and tolerance. In fact, correlations between
gut bacteria composition and the severity of inflammation were first described for
inflammatory bowel diseases and later extended to other pathologies. The genetic
background, environmental factors (e.g., stress or smoking), and diet can induce
strong changes in the resident bacteria which can expose the intestinal epithelium
to a variety of different metabolites, many of which have unknown functions and
consequences. In addition, alterations in gut permeability may allow pathogens entry,
thereby triggering infection and/or chronic inflammation. In this context, a local event
occurring at a mucosal site may be the triggering cause of an autoimmune reaction
that eventually involves distant sites or organs. Recently, several studies attributed
a pathogenic role to altered oral microbiota in rheumatoid arthritis (RA) and to gut
dysbiosis in spondyloarthritis (SpA). There is also growing evidence that different drugs,
such as antibiotics and immunosuppressants, can influence and be influenced by the
diversity and composition of microbiota in RA and SpA patients. Hence, in complex
disorders such RA and SpA, not only the genetic background, gender, and immunologic
context of the individual are relevant, but also the history of infections and the structure
of the microbial community at mucosal sites should be considered. Here the role of
the microbiota and infections in the initiation and progression of chronic arthritis is
discussed, as well as how these factors can influence a patient’s response to synthetic
and biologic immunosuppressive therapy.
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MICROBIOTA AND THE IMMUNE
SYSTEM
Host–microbe interactions are the result of a co-evolution
process, in which both partners have set borders and have
developed mechanisms of tolerance or ignorance. In this context,
hosts were able to establish a continuous connection with
symbiotic bacteria, representing for the host a “gain of function.”
Bacteria provide help for different functions, including the
digestion of complex carbohydrates as well as the absorption and
supply of vitamins (LeBlanc et al., 2013). Worth mentioning is
that, in the complex network of interactions of the microbiome,
the environment should be taken into account since the outbreak
of an infection and/or an inflammatory disease relies on the
complex relationships between the microorganisms, the host, and
the environment (such as dietary components, pollutants and
even drugs) (Kim et al., 2016).
Microbiota are composed of archaea, bacteria, fungi, and
viruses forming a complex ecosystem of which bacteria are
the most well-characterized member. Any microbial imbalance
resulting in a shift (i.e., loss or overgrowth of a species) and/or
reduction in microbial diversity is defined as dysbiosis.
The mucosa has a dual function in our body. It works as
a physical barrier, promoting pathogen exclusion, and is an
absorption site that allows entry of food-derived metabolites and
gas exchange. The mucosal immune system is not fully developed
when we are born because many of the lymphoid structures,
especially in the gut, are formed only upon stimulation through
exposure to microorganisms. In fact, mice bred and maintained
in germ-free conditions have small Payer’s patches and lack
isolated lymphoid follicles (ILF) in their bowel. Furthermore,
serum levels of IgM natural antibodies and IgA secreting cells
in the spleen and intestine are reduced in germ free mice (Rhee
et al., 2004). This phenotype is rescued by gut colonization
once the animals are transferred from isolators to conventional
housing and food. At birth, colonization plays a crucial role
in inducing and shaping the development of the secondary
lymphoid organs as well as setting-up thresholds of reactivity for
both innate and acquired immune responses. Thus, the neonate
microbiota intervenes with the fine balance amongst infection,
inflammation, and tolerance that may “imprint” the immune
system for life.
Recently, Vatanen et al. (2016) followed-up the gut
colonization of children from birth to 3 years of age. Children
from Finland, Estonia and Russia were selected who shared
a human leukocyte antigen (HLA) distribution typical of
individuals at risk for autoimmunity (Vatanen et al., 2016). The
study showed that, depending on the lipopolysaccharide (LPS)
subtype produced by different Bacteroides species, Toll-like
receptor-4 (TLR4) could be either activated or inhibited. This
had an impact on tolerance to endotoxin, and, consequently,
strongly conditioned the genetic predisposition of the infants
to type I diabetes (T1D). Thus, the presence of different LPS
subtypes in the gut could partially explain the difference in
prevalence of early onset autoimmune diseases in Finland and
Estonia compared to Russia. In line with the hygiene hypothesis,
this work adds another clue to the correlation between exposure
or lack of exposure to specific microorganisms in early life and
the increase of autoimmune diseases in western countries.
The microbiota is comprised of both pathogenic and non-
pathogenic bacteria, however, this distinction is not absolute.
A microorganism may behave as commensal or as pathogenic
with regards to the dietary components, nutritional milieu,
broad-spectrum antibiotic treatment, co-infection or genetic
background of its host. Moreover, even though commensals
are by definition not supposed to induce immune responses,
and lamina propria-derived antigen-presenting cells traffic
preferentially to mucosal-associated lymphoid tissue (MALT)
in order to restrict systemic immune responses against the
microbiota, it is possible to find antibodies specific to
commensals in the serum of healthy people, as well as circulating
T cells reactive against non-pathogenic bacteria (Macpherson
et al., 1996; Ergin et al., 2011). Also, in specific genetic
conditions, such as in individuals with defects in interleukin-17
(IL17) signaling pathway, commensal microorganisms become
pathogenic through invasion, causing fungal disease (Puel et al.,
2011). Another condition in which commensals may be harmful
is in mucosal leakage. Changes of permeability at mucosal sites
or altered immune functions strongly condition the persistence
of antigenic stimulation, not only at the place of microbial entry
but also in faraway locations, such as articular sites (Asquith
et al., 2014). Moreover, in frail patients, the administration of
Saccharomyces cerevisiae as a probiotic has been anecdotally
reported to induce sepsis (Montineri et al., 2008; Eren et al.,
2014).
It is worth mentioning here that the microbiota itself
plays a role in regulating the growth of opportunistic enteric
infections, a mechanism termed colonization resistance (Stecher
and Hardt, 2011). Often antibiotic administration, by altering
the equilibrium of the gut microbiota, leads to overgrowth of
Clostridium difficile. This infection represents, nowadays, a major
clinical problem because C. difficile is one of the bacterial species
with higher antibiotic resistance. Microbiota transplantation
from healthy donors, by rescuing microbial equilibrium, has been
one of the most successful strategies to treat serious C. difficile
infection (Hand, 2016).
Bacterial products, such as the previously mentioned LPS,
are sensed by enterocytes through TLRs. Microbial stimulation
of enterocytes induce the production of antimicrobial peptides
(AMPs) and the fucosylation of small intestinal epithelial cells
by Fucosyltransferase 2 (Fut2), both of which can limit specific
infections (Pickard et al., 2014). TLRs regulate innate immune
responses but are also crucial for epithelial cell homeostasis
at mucosal sites. Altered immune function of TLRs, for
example due to different polymorphisms, may change binding
to bacterial products, secretion of cytokines or chemokines,
which consequently interferes with acquired immune cell
generation/migration and inflammation. Thus, it can contribute
to the persistence of inflammatory diseases such as rheumatoid
arthritis (RA) (Rogier et al., 2015).
In addition to bacteria, bacterial-derived products can also
control, directly or indirectly, the function of both epithelial
and inflammatory cells. For example, two important metabolites
are the short-chain fatty acids (SCFAs) and the lipid mediator
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prostaglandin E2 (PGE2). Recognition of the SCFAs by innate
immune cells is important to modulate inflammation in response
not only to intestinal but even to articular damage (Maslowski
et al., 2009). Commensals are also able to regulate the
inflammatory activity of monocytes, by promoting the release
of PGE2 that, in turn, down-modulates the activation of tissue-
damaging neutrophils (Grainger et al., 2013).
The gut is the main site for the generation of the two most
important T cell populations, the inducible regulatory T cells
(iTregs) and CD4IL17-producing cells (Th17), both of which play
critical roles in the development and persistence of autoimmune
disorders. Colonization of the distal small intestine, by segmented
filamentous bacteria (SFB), is fundamental to development of
resident lamina propria dendritic cells (DCs) able to release IL6
and IL22 that trigger the loop of Th17-Treg cell in the newborn
gut (Ivanov et al., 2009; Maslowski et al., 2009). Although many
studies have addressed gut microbiota composition in humans,
we still do not know which would be the “best/healthiest”
microbial composition for the maintenance of the balance
between regulatory (iTregs) and inflammatory (Th17) cells
(Hand, 2016). Recent studies revealed that the homeostasis of
the colonic Treg compartment relies more on the synergistic
effects of different bacterial strains than on a single species of
that strain. This observation strongly suggests the importance
of the entire bacterial community in shaping the appropriate
microenvironment that is able to sustain the production and
maintenance of the anti-inflammatory environment (Atarashi
et al., 2013).
ORAL/GUT DYSBIOSIS AND ARTHRITIS
Rheumatoid arthritis and Spondyloarthritis (SpA) are chronic
inflammatory autoimmune diseases potentially leading to quality
of life impairment and reduction in life expectancy. RA is
characterized by the presence of autoantibodies [rheumatoid
factor (RF) and anti-citrullinated protein antibodies (ACPAs)]
and is characterized clinically by the emergence of erosive
synovitis predominantly involving small joints, such as hands,
wrists, and feet. The reported prevalence of the disease is 0.5–1%
in the general population (Hayter and Cook, 2012).
Spondyloarthritis is a pleomorphic group of conditions that
includes ankylosing spondylitis (AS), psoriatic arthritis (PsA),
reactive arthritis (ReA), SpA associated to inflammatory bowel
disease (IBD), acute anterior uveitis and axial non-radiographic
SpA. The reported prevalence for AS is 2.4/1,000 (Dean et al.,
2014). Arthritis is the most frequent extra-intestinal disease
manifestation in patients with IBD (range 15–40%); conversely,
up to 60% of patients with SpA present subclinical gut
inflammation and 10% overt inflammation evolving to Crohn’s
disease (Mielants et al., 1995; De Vos et al., 1996; Olivieri et al.,
2014).
The evidence of a direct role for the gut microbiota in the
development of autoimmune arthritis arises from experimental
studies on germ-free mice in which a reduced severity and/or
incidence of arthritis has been demonstrated (Carding et al.,
2015).
However, in man, a direct correlation between gut dysfunction
and systemic inflammation has been clearly established only
in AS. Some studies by Ciccia et al. (2012) have identified
several alterations of the ileum architecture in AS patients that
may be the cause for chronic inflammation, both local and
systemic. AS patients showed disruption of the basal membrane
with compromised epithelial cell permeability, hyperplasia of
goblet cells (with increased mucins production) (Ciccia et al.,
2012) and activation of Paneth cells, producing high levels
of adenosine monophosphate, such as α-defensin 5 (Ciccia
et al., 2010) and proinflammatory cytokines, such as IL23
(Ciccia et al., 2009). These characteristics may be the cause
or the consequence of dysbiosis, with changes in the diversity
of the commensal bacteria (Costello et al., 2015). Increased
intestinal permeability, probably determined by genetic factors
such as HLA-B27 expression (Rosenbaum and Davey, 2011; Lin
et al., 2014; Bowness, 2015), results in continuous antigenic
stimulation with activation of effector T cells. These effector
cells do not show a clearly defined Th17, Th1, and/or Th9
polarization, due to the over-expression of an IL23 response
by Paneth cells (Ciccia et al., 2009). Worth noting is that
IL23 can regulate the maturation of autoreactive Th17 cells
but can also induce chronic inflammation by stimulating IL17,
IL6, IL8, and tumour necrosis factor (TNF)-α production in
neutrophils and macrophages. Furthermore, a link between
IL23R polymorphisms and susceptibility to psoriasis, PsA and AS
have been shown (Liu et al., 2008).
In patients with PsA, subclinical gut inflammation is
characterized by the overexpression of IL9 and the generation of
Th9, Th17, and Th22 responses. Th9 cells produced in the gut
are found to be increased in the peripheral blood and they are
able to migrate, enter synovial tissues and become established. In
the meantime, gut-activated Paneth cells express both IL9 and IL9
receptors, creating a positive autocrine loop that perpetuates local
inflammation (Ciccia et al., 2016).
Solid data suggest that alterations in the oral microbiota can
influence both progression and disease outcome in RA patients
(Diamanti et al., 2016; Table 1). It has been speculated that certain
species of bacteria, mainly Porphyromonas gingivalis (PG) which
may be present in the oral cavity, and are increased in patients
affected by periodontitis, can induce loss of tolerance and lead
to citrullination of several peptides and proteins (Wegner et al.,
2010; Quirke et al., 2014; Ciccia et al., 2016).
Citrullination is a post-translational modification that
converts arginine residues into citrulline leading to relevant
changes in the protein structure, charge and function.
Porphyromonas gingivalis peptidyl-arginine-deiminases enzyme
(PPAD) can catalyze citrullination on different self-proteins
(mainly α-enolase and fibrinogen) thus resulting in immune
evasion by these neo-epitopes and the production of ACPAs
(McInnes and Schett, 2011).
Indeed, it has been reported a direct correlation exists between
the serum level of antibodies to PG and ACPAs in RA patients
(Mercado et al., 2001; Dissick et al., 2010; Scher et al., 2012;
Lange et al., 2016). This observation has been confirmed by the
increased prevalence of PG-induced periodontitis in RA patients
as compared to healthy individuals. Likewise, other studies
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TABLE 1 | Most frequently reported dysbiosis in RA and SpA patients and the proposed pathogenic mechanisms.
Autoimmune arthritis Dysbiosis Pathogenic mechanisms
Increased amount Decreased amount
Rheumatoid arthritis Porphyromonas gingivalis (PG) (periodontitis
induced by PG is a poor prognostic factor of
response to anti-TNFα therapy)
Lactobacillus salivarius
(active RA)
Prevotella copri spp. (RA)





Haemophilus spp. (active RA)
Bacteroidetes phylum members (RA)
Common commensals such as:
Bifidobacteria and Bacteroides (early RA)
PG peptidyl-arginine-deaminase
enzyme can catalyze citrullination on
different self-proteins (mainly α-enolase
and fibrinogen) thus resulting in the
immune evasion to these neo-epitopes






The genus Dialister positively correlated with
SpA activity
Sulphate-reducing bacteria (AS)
Firmicutes (skin of PsA patients)
Veillonellaceae and Prevotellaceae (SpA)





(stool of PsA patients)
Actinobacteria, Propionibacteria spp
(skin of PsA patients)
Disruption of the gut basal membrane
with compromised epithelial cell
permeability, hyperplasia of goblet cells
and activation of Paneth cells.
Continuous antigenic stimulation with
activation of effector T cells.
RA, rheumatoid arthritis; SpA, spondyloarthritis; PsA, psoriatic arthritis; ACPAs, anti-citrullinated protein antibodies.
have demonstrated that the presence of periodontitis is a poor
prognostic factor in RA patients treated with anti-TNFα agents.
The clearing of a periodontal infection can reduce the severity of
active RA and lead to a better disease outcome during synthetic
and biologic immunosuppressant treatment (Ortiz et al., 2009;
Savioli et al., 2012; Kaur et al., 2014).
In line with the above described observations, a case of
complete and long-lasting recovery in a patient with early RA
after PD treatment has been recently reported, suggesting that,
at the onset of disease, periodontitis treatment may avoid the
development of a chronic and progressive arthritis (Salemi et al.,
2014).
The influence of the intestinal microbiota on RA is still a
matter of debate. A lower representation of common commensals
such as Bifidobacteria and Bacteroides species (Vaahtovuo et al.,
2008) and an increase in Mycoplasma fermentans (Johnson
et al., 2000), Escherichia coli (Newkirk et al., 2010) and
Proteus mirabilis (Senior et al., 1999) has been reported
in early RA patients, whereas another study showed that
stool samples from early RA patients had significantly more
Lactobacillus communities than healthy subjects (Liu et al.,
2013). In patients with long-standing RA a decreased gut
microbial diversity seems to correlate with disease duration
and autoantibody levels as well as expansion of rare genera,
Collinsella, Eggerthella, and Faecalibacterium (Chen et al., 2016).
Other authors have reported, in the fecal microbiota of RA
patients, an increase of Prevotella copri spp. with concomitant
reduction of Bacteroidetes phylum members (Scher et al.,
2013). Recently Zhang et al. (2015) described a dysbiosis
of both fecal and oral samples from RA patients using
metagenomic shotgun sequencing and a metagenome-wide
association study; these concordant abnormalities in mouth
and gut microflora were restored after immunosuppressive
treatment. In particular, Haemophilus spp. was strongly reduced,
whereas Lactobacillus salivarius was increased especially in oral
microbiota of patients with active RA disease (Zhang et al., 2015;
Table 1).
The role of the gastrointestinal tract in the pathogenesis
of SpA was proposed by Costello et al. (2015) who have
evaluated biopsy specimens from 9 early SpA patients finding a
higher abundance of five families of bacteria (Lachnospiraceae,
Ruminococcaceae, Rikenellaceae, Porphyromonadaceae, and
Bacteroidaceae), accompanied by a reduction of Veillonellaceae
and Prevotellaceae with respect to healthy controls. Tito et al
analyzed the gut microbiota (colon biopsy specimens) of 27
patients with SpA and 15 healthy controls and showed that
the intestinal inflammation was associated with the mucosal
microbiota composition. Of particular interest, they found that
the genus Dialister positively correlated with the SpA activity
(Tito et al., 2016). Stebbings et al. (2002) were the first group
that reported differences in the fecal samples of AS patients
compared to healthy controls by using molecular analysis. They
did not find significant differences in the microbiota composition
but did find a higher proportion of sulfate-reducing bacteria in
AS patients (Stebbings et al., 2002). Fecal samples and blood
specimens obtained from children with enthesitis showed less
Faecalibacterium prausnitzii spp. and Lachnospiraceae family
members and a significant increase in the Bifidobacterium
genus (Stoll et al., 2014). Finally, other authors have reported a
significant increase in Firmicutes associated with a reduction in
members of Actinobacteria phylum and Propionibacteria spp in
the skin samples of patients with psoriasis, compared to healthy
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controls (Fahlén et al., 2012). The gut microbiota observed
in patients with PsA also showed limited diversity compared
to healthy controls. In particular, it has been demonstrated
that there is a decrease in the bacterial genus Akkermansia,
Ruminococcus, and Pseudobutyrivibrio in fecal samples from PsA
patients (Scher et al., 2015; Table 1).
There is a growing awareness that the microbiota diversity
and composition can influence a patient’s response to synthetic
and biologic immunosuppressive therapy. Immunosuppressive
drugs, such as cyclophosphamide and methotrexate (MTX), can
induce a diffuse depletion of the gut microbiota associated with a
decrease in the commensal anaerobic species in favor of potential
pathogens that can damage the gut barrier, altering epithelial
cell permeability with consequent bacterial translocation (Viaud
et al., 2013; Karin et al., 2014). Different authors have underlined
the importance of an intact intestinal microbiota in the response
to sulphasalazine (SSA), a synthetic drug frequently used in
autoimmune arthritis. They found a decreased efficacy of SSA
therapy in patients with ulcerative colitis previously treated with
severe antibiotic regimens (Das et al., 1973; Peppercorn and
Goldman, 1972). Conversely, the use of a multi-strain probiotic
regimen does not seem to interfere with the metabolism of SSA
in RA patients (Lee et al., 2010).
By now, data on the impact of microbiota in patients receiving
immunosuppressive biologics are limited and only refer to
IBD patients. One research group has found a reduction in
the bacterial species Firmicutes phylum in patients affected by
relapsing Crohn’s disease as compared to clinically stable patients
with administration of anti-TNFα agents. This modification in
gut microbiota was associated with a reduction in F. prausnitzii
spp. predicting clinical relapse of the Crohn’s disease (Rajca et al.,
2014). More recently, Busquets et al. (2015) have demonstrated
that adalimumab (fully human anti-TNFα monoclonal antibody)
could partially restore a healthy microbiota in a small group of
patients affected by Crohn’s disease. Treatment resulted in the
recovery of Firmicutes, Bacteroides and Actinobacteria diversity
species whereas E. coli spp. was decreased (Busquets et al., 2015).
INFECTIONS AND ARTHRITIS
In autoimmune arthritis, such as RA and SpA, the hypothesis
of an infectious event as the cause for disease induction and
relapse has been under consideration for a long time. Arleevskaya
et al. (2014) have shown during a 10-year follow-up study
that minor infections are more frequent and prolonged in RA
patients and their relatives than in families without a history of
autoimmunity. This study suggests a role for some predisposing
defects of anti-bacterial defense mechanisms, more than for a
specific microorganism. However, although by now no causative
pathogen has been clearly identified nor a direct correlation with
a specific infection has been established, it does not imply its
absence. In fact, many pathogens have been indicated as possible
triggers for RA disease but heterogeneity of the studies impairs
forming any conclusions (Arleevskaya et al., 2016).
The most intriguing and supported idea for a role of
infection in triggering RA, is that the microorganism can enter
to and be located in the intestine, lungs or mouth; where it
can interact with environmental factors such as smoke and
drugs and, with a genetic predisposition, lead to mucosal
inflammation. This, in turn, results in increased immune
activation and spreading of inflammatory mediators, which
locally perpetuate the disease. Exacerbated immune activation
may also lead to aberrant migration of intestinal macrophages
and lymphocytes from inflamed mucosa to the joints (Salmi et al.,
1995).
The complex and interwoven link between microbes and joint
inflammation is a frequent challenge for clinicians.
A severe increase in the serologic inflammatory parameters
(i.e., erythrocyte sedimentation rate and C reactive protein),
induced by a concomitant infection in a patient with autoimmune
arthritis under immunosuppressive therapy is commonly
encountered in the rheumatologic clinical practice. Indeed, the
stimulation of systemic inflammation induced by the infectious
pathogen can resemble a reactivation of the autoimmune
arthritis, leading clinicians to increase the immunosuppressive
therapy with a consequent worsening and dissemination of the
infection.
The link between microbes and arthritis also has a
broad spectrum of clinical expression. In fact, it can range
from septic arthritis, in which the pathogen is directly
responsible for joint inflammation and damage, to ReA. In
the latter, infections by microorganisms, mainly Gram negative,
such as Chlamydia trachomatis, Yersinia, Salmonella, Shigella,
and Campylobacter (Espinoza and García-Valladares, 2013),
find a genetically predisposed background (i.e., HLAB27)
eventually resulting in chronic inflammation. However, the
mechanism underlying the immune stimulation and consequent
migration to distant synovial tissue is poorly understood
(Keat et al., 1978; Granfors et al., 1990; Merilahti-Palo et al.,
1991). It is worth mentioning that T cell clones specific
for enteric bacteria have been found in synovial tissue of
patients with ReA (Hermann et al., 1990; Probst et al.,
1993).
It can be argued that the early recognition and eradication of
the infective focus can lead to a resolution of the inflammatory
stimulus and consequent interruption of the chronic immune
loop. This can be the case of periodontal treatment in early RA,
antibiotic therapy for beta-hemolytic Streptococcus in rheumatic
fever and anti-hepatitis C virus (HCV) treatment for mixed
cryoglobulinemia.
Recently, Campisi et al. (2016) using a complex and elegant
set of experiments in mice, demonstrated that microbial infection
at mucosal sites can elicit a break in tolerance by promoting
the presentation of self-antigens derived from epithelial cell
apoptotic bodies. Apoptosis of infected colonic cells leads to the
generation of both anti-pathogen and autoreactive T cells, mainly
Th17 cells, with production of auto-antibodies and inflammation
(Campisi et al., 2016). These results have important implications
for understanding how infections can stimulate the development
of autoimmunity in an immunological context different from
bystander activation of autoreactive T cells or epitope mimicry.
Further studies are needed to establish similar correlations in
humans.
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The risk of infections in autoimmune patients is higher
than in healthy individuals, due to endogenous (dysfunctional
immune system) and external factors (i.e., comorbidities and
immunosuppressive therapy). The risk has been reported to
be approximately double for infections of bone and joints,
skin, soft tissues and respiratory tract (Myllykangas-Luosujarvi
et al., 1995). Moreover, it is known that infections can induce
disease relapses, present a more severe clinical outcome and can
be a frequent cause of death in immune-suppressed subjects
(Gonzalez et al., 2007).
Immunosuppressive treatment is the main exogenous
factor contributing to the increased risk of infections in
autoimmune patients. TNFα blocking agents are the first
biological immunosuppressive therapy approved for both RA
and SpA. Currently five different drugs targeting TNFα are
available: infliximab (the first antibody to be approved) is a
chimeric monoclonal antibody (mAb) with approximately one
third murine and two thirds human sequences; adalimumab, a
fully human mAb produced by chinese hamster ovary (CHO)
cells; golimumab a fully human mAb; certolizumab pegol, a
poly-etyhlene-glycol (PEG)ylated humanized Fab’ fragment; and
etanercept a fusion protein that consists of the p75 part of TNFR2
and a human IgG1 Fc domain (Salemi et al., 2015; Dieterich
et al., 2016). Although these agents have shown a good safety and
efficacy profile, up to 40% of the patients may present a primary
or secondary drug failure or treatment-related adverse events
(Day, 2002).
In the last decade, several research groups have studied in
depth the molecular pathways involved in the development of
autoimmune arthritis, allowing identification of new therapeutic
targets. Among those, the anti-CD20 chimeric mAb (rituximab)
(de la Torre et al., 2012); the humanized anti-human IL6 receptor
mAb (tocilizumab) (Nishimoto et al., 2007), and the CTLA-4-
Ig (abatacept), a fusion protein that works as an inhibitor of
T cell activation (Moreland et al., 2006), are currently available
for RA patients. More recently, mAb against the p40 subunit
of interleukin 12/23 ustekinumab (Gottlieb et al., 2009) and the
mAb against the IL17A, secukinumab have been introduced for
the treatment of patients with SpA (Patel et al., 2013).
Different authors have evaluated the infection risk induced
by corticosteroids (CS) as well as synthetic and biologic
immunosuppressant drugs in SpA and RA patients. Studies
generally showed that synthetic immunosuppressive therapy
(mainly MTX), is relatively safe, whereas data on the possible
increase in the number and/or severity of infections in
patients taking TNFα blocking agents are contrasting. Doran
et al. (2002) showed that the use of CS, older age, extra-
articular manifestations of RA, leukopenia, and comorbidities,
are strong predictors of infections, whereas the use of synthetic
immunosuppressive agents was not associated with increased
risk. These results were partially confirmed by Lacaille et al.
(2008), who reported an increased risk of infections in RA
patients taking CS, but not synthetic immunosuppressive
therapy. Data on the infection risk for biologic drugs derives
mainly from national registries among which are the British
Biologics Register and the RABBIT German Registry. Data from
these registries estimated a two-fold increased risk of serious
infections which was directly related to the dose of CS, mainly
when CS were associated with TNFα inhibitors (Dixon et al.,
2006; Zink et al., 2014). Results obtained from meta-analysis
studies have also indicated a significant increase in the occurrence
of serious infections (40%), in patients receiving anti-TNFα
agents, while the data for opportunistic infections were not
conclusive (Bongartz et al., 2006; Minozzi et al., 2016).
We have recently described, in a retrospective observational
cohort study, that the combination of anti-TNFαwith CS appears
to be the most “pro-infective” treatment, whereas synthetic
immunosuppressant drugs, either alone or associated with CS,
were relatively safe in both patients with RA or with SpA
(Germano et al., 2014). In contrast with these real-life data,
the placebo-controlled trials evaluating TNFα blockers in RA
patients, did not find a higher rate of infections in treated patients
with respect to the placebo group (Lipsky et al., 2000; Klareskog
et al., 2004; Weinblatt et al., 2005).
CONCLUSION
Patients with autoimmune arthritis are at high risk of infections,
due to endogenous (dysfunctional immune system) and external
factors (i.e., comorbidities, drugs).
Infections can induce disease relapses and be characterized
by a severe clinical outcome in these patients, representing a
frequent cause of death. Furthermore, the stimulation of systemic
inflammation induced by the infectious pathogen, mimicking a
reactivation of the autoimmune arthritis, frequently represents a
confounding and dangerous factor for clinicians.
In the last few years the efforts of several researchers have
focused on the gut and mouth microflora leading to the
identification of specific abnormalities in both its composition
and diversity. In susceptible individuals, the presence of PG
could be a trigger factor for RA development by inducing the
generation of citrullinated proteins via a PPAD enzyme on
different self-proteins that results in the production of ACPAs.
In SpA patients the increased intestinal permeability, probably
induced by genetic factors (e.g., HLA-B27) could lead to a
disruption of the basal membrane, hyperplasia of goblet cells and
activation of Paneth cells producing high levels of AMPs and
IL23. It would result in a continuous antigenic stimulation with
activation of effector T cells.
Careful monitoring for infectious foci, especially in the mouth
and intestine, should be recommended in order to allow their
early recognition and eradication, thus resulting in removal of the
inflammatory stimulus, inhibition of the chronic immune loop
and improvement of the arthritis.
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